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ABSTRACT 
Chalcone compounds have been known to possess anticancer activity. The present study is a preliminary 
investigation on the anticancer potential of eight newly-synthesized chalcone compounds towards CaoV-3 cell 
line. Vero cell line, which was commonly used in the laboratory, was used as a standard. Eosin B staining assay 
method revealed that the compounds CI and C2 possessed high cytotoxic effect towards cancer cells following a 
48-hour incubation period. The anticancer activity ofCI at 25 )lglml and 100 Ilglml, and C2 at 50 )lglml and 100 
Ilglml did not differ significantly from the positive control at p=0.05. This suggests that the compounds were as 
effective as the positive control in killing the cells at these concentrations. C7 has also been shown to be a good 
candidate for developing into an anticancer drug, since the compound was mildly cytotoxic to Vero cells at 72­
hour incubation period and showed a large difference in cytotoxicity between 50 Ilglml and 100 Ilglml, which 
implie that controlled dosage of C7 can be used to regulate its activity. Structure-activity relationship (SAR) 
analy is showed that the intensity of anticancer activity was influenced by the location of substituent group (in 
ring A or ring B), their positions within the aromatic ring, and the chain length of hydrocarbon substituents. In 
addilion, RT-PCR was performed to detect the expression level of Cox-2 gene in order to evaluate the capability 
of the compounds in suppressing Cox-2 gene expression. However, no Cox-2 band was detected in all of the 
samples studied. One postulation for this observation was the defect in the primers used. Nonetheless, further 
test.... such as DNA sequencing or the use of different sets of Cox-2 primers, need to be carried out to confirm the 
postulation. 
Keywords: Anticancer, Chalcone, Cox-2, Cytotoxicity testing, RT-PCR 
ABSTRAK 
Sebatian calkon telah lama dikenali untuk memiliki aktiviti antikanser. Kajian ini merupakan kajian awal untuk 
menyiasat potensi antikanser lapan sebatian calkon yang baru dengan mengenal pasti keberkesanan sebatian­
sebaJian tersebut dalam menghasilkan kesan sitotoksik khas kepada sel CaoV-3, dengan menggunakan sel Vero 
yang biasa digunakan di dalam makmal sebagai satu piawai. Vjian sitotoksik menggunakan kaedah perwarnaan 
eosin B menunjukkan bahawa sebatia CI dan C2 memiliki kesan sitotoksik yang tinggi terhadap sel kanser 
seJepas inkubasi selama 48 jam. Tiada perbezaan signifikan antara aktiviti antikanser CI pada 25 jlg/ml dan 100 
jlg/ml serta C2 pada 50 jlg/ml dan 100 jlglml daripada kawalan positij di p=0.05. Ini mencadangkan bahawa 
kecekapan membunuh sel sebatian-sebatian ini pada konsentrasi-konsentrasi tersebut adalah setinggi kawalan 
positi[ Selain itu, C7 juga merupakan calon ubat antikanser yang baik, memandangkan sebatian ini mempunyai 
wan sitotoksik yang rendah terhadap sel Vero pada tempoh inkubasi selama 72 jam, dan menunjllkkan 
perbezaan kesan sitotoksik yang besar antara 50 jlglml dan 100 jlglml. Ini mencadangkan bahawa aktiviti C7 
boleh dikawal dengan mengubahsuai dos yang digunakan. Analisis hubllngan struktur-aktiviti menllnjukkan 
bahawa intensiti aktiviti antikanser dipengaruhi oleh lokasi (di einein A atau eincin B), posisi dalam cinein 
aromalik. dan kepanjangan rantai hidrokarbon kumpllian-kumpulan pengganti. Selain itu, RT-PCR telah 
dijalankan untllk memerhati tahap ekspresi gen Cox-2 bagi menilai kebolehan sebatian-sebatian tersebut dalam 
menekan ekspresi gen tersebut. Walau bagaimanapun, tiada band Cox-2 diperhatikan dalam kesemua sampel 
yang dikaji. Salah sam postlliasi IIntllk pemerhatian ini ialah kerosakan primer-primer yang digunakan. Namun, 
ujian yang !,elanjutnya, seperti penjujukan DNA atall penggunaan set-set primer Cox-2 yang ber/ainan, per/u 
dijalankan untllk memastikan kesahihan postlliasi tersebut. 
Kalil /cunei: Antikanser, Calkon, Cox-2, RT-PCR, Vjian sitotoksik 
1 
1.0 Introduction 
Cancer is a genetic disorder characterized by the formation of malignant neoplasm due to the 
defects in normal cellular programs which control cell proliferation and cell death (Cooper, 
1992; Nussbaum et ai., 2004). If left untreated, cancer can eventually result in the death of the 
affected individuals. World Health Organization (2009) has reported that cancer contributed to 
approximately 7.4 million mortality cases in 2004 alone. More importantly, the number of 
deaths is expected to rise significantly in subsequent years. Hence, the search for effective 
anticancer drugs has now become a central focus of research for developing therapeutic 
treatment for the disease. 
The potential role of chalcones as anticancer drugs has been studied extensively (Anto 
et al. , 1995; Ducki, 2007; Modzelewska et ai., 2006). These compounds, which consist of two 
aromatic rings joined by a three-carbon a,p-unsaturated carbonyl system, occur naturally in 
many plants. In recent years, chemical synthesis has become possible, principally through 
Suzuki coupling reaction (Eddarir et ai., 2003), von Konstanecki condensation (von 
Konstanecki & Rossbach, 1896) or Claisen-Schmidt condensation (Dong et ai., 2008) 
(Appendix A). 
Chalcones have been shown to possess many pharmacologically important biological 
activities, including antioxidant (Anto et ai., 1995), anti-inflammatory (Herencia et ai., 1998) 
and antimicrobial (Tomar et ai., 2007), among others. The intensity of these bioactivities is 
influenced primarily by the type, size, and location of substituent groups present in their 
aromatic rings. 
2 
A series of new chalcone compounds with alkoxy and hydroxyl substituents (Appendix 
B) has recently been synthesized by researchers in the Department of Chemistry, Faculty of 
Resource Science and Technology, Universiti Malaysia Sarawak. The presence of the 
substituent groups in these compounds is thought to contribute to the various biological 
activities. Indeed, a previous study by Leong (20lO) has shown that some of these chalcone 
compounds possess high antibacterial activity. 
However, no study has yet been done to investigate the anticancer activity of these 
chalcone compounds. This study therefore focuses on screening the compounds for their 
potential anticancer activity by fIrst carrying out in vitro cytotoxicity test on CaoV-3 cells at 
different chalcone concentrations and exposure periods. The cytotoxicity test was carried out 
by using eosin B staining method and the viability of the cells was measured after compound 
treatment. Further, reverse transcription polymerase chain reaction (RT-PCR), was performed 
to detect the level of expression of Cox-2 gene, an oncogene which is commonly 
overexpressed in a variety of cancer cells, to determine the effectiveness of the compounds in 
suppression the expression of the gene. 
The objectives of this study are: 
• 	 To investigate the cytotoxicity of the chalcone compounds on CaoV-3 and Vero cells. 
• 	 To detect the level of expression of Cox-2 gene for determining the effectiveness of 
chalcone compounds in suppressing the expression of the gene. 
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2.0 Literature Review 
2.1 Chalcone compounds 
Chalcones, or 1,3-diphenyl-2-propen-l-ones, are a class of flavonoids characterized by the 
absence of a heterocyclic C ring. The basic skeleton of chalcones consists of two aromatic 
rings joined by a three-carbon (l,~-unsaturated carbonyl system (Figure 1), and has a chemical 
fonnula of C1sH I20. Chalcones are found naturally and abundantly in a variety of plants, 
including those of the genera Pityrogramma, Xanthorrhoea, Paeonia and Coreopsis (Harborne, 
1966). These compounds serve as important intennedjate precursors in the biosynthesis of 
various flavonoids, such as flavonols (Grisebach & Patschke, 1961), anthocyanins (Grisebach 
& Patschke, 1961), flavanones (Wong, 1965), and catechins (Patschke & Grisebach, 1965). In 
addition, chalcones can be chemically synthesized in the laboratory, chiefly through Suzuki 
coupling reaction (Eddarir et ai., 2003), von Konstanecki condensation (von Konstanecki & 
Rossbach, 1896) or Claisen-Schmidt condensation (Dong et ai., 2008) (Appendix A) of 
appropriate aromatic ketones or substituted aromatic ketones with benzaldehydes or 
substituted benz aldehydes in the presence of base or acid. Chalcone compounds can exist 
either in E or Z configuration, with the fonner being more stable thennodynamically (Go et ai., 
2005). 
o 
Figure 1: The basic skeleton of chalcone compounds. 
4 
"'~tf Khldmat Mlkiumat .4'ad~mfk 
UNJV~RSm MALAVSIA SARA\ AJ( 
2.1.1 Physical properties of chalcone compounds 
Chalcone compounds typically have a boiling point of between approximately 345°C and 
348°C, and a melting point of about 55°C to 57°C. The boiling and melting points, however, 
vary from one compound to another, depending on the type of substituent groups present in 
their aromatic rings and thus their specific chemical structures. In general, chalcones exist as 
solid at room temperature and appear yellow in color (Laliberte et al., 1967). The compounds 
have a density of 1.071 g/cm3 and a vapor density of 7.18 (air = 1). They are very slightly 
soluble in cold water. 
2.1.2 Pharmacological value of chalcones 
Chalcones have been shown to possess many biological activities, which are of 
phannacological importance. These include antiviral (Onyilagna et al., 1997), anti-
inflammatory (Rojas et al., 2002), antimicrobial (Tomar et aI., 2007), anti-diabetic (Jamal et 
al., 2009), and most notably anticancer (Anto et al., 1995; Modzelewska et al., 2006) activities, 
among many others. For example, various chalcone derivatives have been shown to be able to 
inhibit cancer cell proliferation and angiogenesis in both primary cancer samples as well as in 
established cancer cell lines (de Vincenzo et al., 1995; Shibata, 1994). The compounds have 
also been shown to be able to prevent skin carcinogenesis in vivo (Satomi, 1993; Yamamoto et 
al., 1991). The biological activity of the chalcone compounds is thought to be influenced by 
their structures (Nerya et al., 2004; Prasad et al., 2008), which are detennined primarily by the 




Cancer refers to a group of diseases developed as a result of uncontrolled cell proliferation 
(Cooper, 1992). This occurs when mutations occur to proto-oncogenes, tumor suppressor 
genes, and/or DNA repair genes (Hinds & Weinberg, 1994; Munro, 200 I; Bronner, et at., 
1994). These mutations cause the normal biomolecular circuits for cell division and cell death 
to become dysregulated, leading to the formation of a mass of celts called tumor or neoplasm 
(Kline et aI., 2001). Tumors can, however, be classified into benign or malignant, and only 
malignant tumors contribute to the development of cancer. Since every cell types have the 
possibility to become cancerous, more than 200 types of cancer have been identified to date 
(Pelengaris & Khan, 2006). These can be classified into four main forms, namely sarcomas, 
carcinomas, hematopoieic malignancy or lymphoid malignancy (Weinstock, 2004). 
Most, if not all, of human cancers manifest six essential physiological changes at the 
cellular level, which are commonly referred to as the hallmarks of cancer (Hanahan & 
Weinberg. 2000). These are summarized in Table 1. 
Table 1: Six hallmarks of cancer (adapted from Hanahan & Weinberg, 2000) 
Hallmark ofcancer Example of mechanism 
Self-sufficiency in growth signals Activate H-Ras oncogene 
Insensitivity to anti-growth signals Lose retinoblastoma suppressor 
Evading apoptosis Produce insulin-like growth factor (IGF) survival 
factors 
Limitless replicative potential Tum on telomerase 
Sustained angiogenesis Produce vascular endothelial growth factor 
(VEGF) inducer 
Tissue invasion and metastasis Inactivate E-cadherin 
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2.3 Mechanism of anticancer drugs 
Thus far, many potential anticancer drugs have been discovered. These drugs function by 
targeting various components thought to be important in the development and progression of 
cancer, such as microtubule (Jordan, 2002), cell cycle checkpoints (Shapiro & Harper, 1999) 
and DNA topoisomerases (Nelson et at., 1984). Despite the many different targets of 
anticancer drugs, all of them exert their antitumor effects by killing twnor cells through 
apoptosis (Kim et at., 2002). Anticancer drug-induced apoptosis can occur through two major 
pathways, namely the mitochondrial pathway and the death receptor-dependent pathway 
(Solary et al. , 2002). 
The mitochondrial pathway is concerned mainly with the killing of cells by releasing 
substances normally found in the mitochondrial intermembrane space into the cytosol. Many 
mechanisms have been suggested for the release of such substances, and it is thought that the 
mechanism differs from cell type to cell type. For example, anticancer drug may act by 
inducing proapoptotic protein of Bcl-2 family, such as Bak or Bax, to cause pore formation in 
the external membrane of mitochondria (Antonsson et at., 1997; Eskes et at., 2000), or to 
penneabilize the voltage-dependent anion channel (VOAC) located on the outer mitochondrial 
membrane (Shimizu et at., 1999). Anticancer drugs have also been proposed to stimulate the 
adenine nucleotide trans locator (ANT) to form pore in the inner mitochondria membrane, 
which lead to the loss of transmembrane potential and therefore the swelling of mitochondria 
and the eventual burst of its outer membrane (Zarnzami et al., 1995). Regardless of the 
mechanisms, these events contribute to cell apoptosis by allowing outflow of heme-binding 
holocytochrome c and/or flavoprotein apoptosis inducing factor (AlF). 
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The flow of holocytochrome c and AIF can lead to two different apoptosis pathways, 
i.e. caspase-dependent apoptosis and caspase-independent apoptosis, respectively. On one 
band, the release ofholocytochrome c into cytosol leads to the caspase-dependent apoptosis by 
promoting oligomerization of apopotic protease activating factor 1 (AP AF-1). As a result, its 
caspase recruitment domain becomes exposed, and this causes the activating factor to interact 
with procaspase-9, resulting in the juxtaposition of two procaspase-9 molecules (Hu et al., 
1999). This, in tum, leads to the release of active caspase-9. The active caspase-9 can then 
activate the downstream caspase cascade by cleaving and activating caspase-3 and caspase-7, 
eventually leading to apoptosis (Kim et al., 2002; Slee et al., 1999). On the other hand, the 
outflow of AIF results in caspase-independent apoptosis, by introducing various changes to the 
cell nucleus (Susin et al., 1999). 
The death receptor-dependent pathway is mediated by Fas, which is the death receptor 
in cells. It has been suggested that anticancer drugs can induce the binding of Fas ligand to it, 
resulting in the clustering of Fas (Micheau et ai., 1999). This stimulates the formation of a 
death inducing signaling complex (DISC), which consists of the adaptor protein F ADD (Fas­
associated death domain) that binds to procaspase-8 and to the death domain located on the 
inttacellular part of Fas (Chinnaiyan et al., 1995; Medema et al., 1997). Oligomerization of 
procaspase-8 in DISC causes the release of active caspase-8. The caspase-8 can then cleave 
caspase-3, which eventually leads to downstream caspase cascade and the occurrence of 
apoptosis. 
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1.4 Cyclooxygenase-2 (Cox-2) 
Cyclooxygenase-2 (EC 1.14.99.1), also known as Cox-2 or prostaglandin-endoperoxide 
synthase 2, is an enzyme involved in the synthesis of prostaglandin in response to events such 
as injury, inflammation or proliferation (Hla & Neilson, 1992; Tazawa et al., 1994). The 
enzyme is encoded by the Cox-2 gene, which has been mapped to the locus lq25 of human 
chromosome (Tay et al., 1994). The gene has been found to be constitutively expressed in the 
tissues of brain (Breder et al., 1995), kidneys (Harris et al., 1994) and lungs (Ermert et al., 
1998). However, in most other tissues, the expression of the gene can be induced by 
proinflammatory or mitogenic stimuli, including cytokines, endotoxin, and growth factors 
(Habib et al., 1993; Hempel et al., 1994). In addition, the expression of Cox-2 has also been 
shown to be up-regulated in a variety of cancers, including colorectal cancer (Sano et al., 
1995), gastric cancer (Ristimaki et al,. 1997), pancreatic cancer (Tucker et al., 1999), breast 
cancer (Soslow et al., 2000), lung cancer (Soslow et al., 2000), cervical cancer (Kulkarni et al., 
2001), and ovarian cancer (Gu et al., 2008). 
1.5 CaoV-3 cell line 
CaoV-3 is a human ovarian papillary adenocarcinoma cell line. Since ovarian adenocarcinoma 
is one of the top death-causing cancer types among women (Jemal, 2008), the cell line has 
been used in various cancer-related research, including drug testing, gene expression analysis 
and toxicological studies, among others (Min et al., 2001; Zhang et al. , 2004; Zhang et al., 
2009). CaoV-3 cells were first isolated from the ovary of a 54-year-old Caucasian female in 
1976. The cells are adherent and grow well when cUIltured in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% fetal bovine serum, and incubated at 37°C in a 
·tion which provides 5% carbon dioxide. 
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3.0 Materials and Methods 
3.1 Cell culture 
Vero and CaoV-3 cells were obtained from culture collection of Animal Tissue Culture 
Laboratory of FRST, UNIMAS. The Vero cells served as a standard for the cytotoxicity 
testing (Syarifah, 2011). The frozen cells were thawed and cultured in appropriate culture 
medium (CaoV-3, Dulbecco's Modified Eagle's Medium (DMEM) with high glucose content; 
Vero, Dulbecco's Modified Eagle's Medium (DMEM) with low glucose content) 
supplemented with 5% fetal bovine serum (FBS) and 1% penicillin. The cells were then 
incubated at 37.0°C in 5% C02, where the cultured cells grow best. Renewal of media was 
perfonned whenever the media have turned yellow, an indication of the drop in pH. Splitting 
or subculture of cells was carried out whenever the cells have reached a confluency of 
approximately 80%, and occasionally, the cells were cryopreserved for future use. 
3.2 Preparation of chalcone compounds and controls 
The eight chalcone compounds used in this study (Appendix B) were obtained from the 
Organic Chemistry Laboratory, Department of Chemistry, FRST, UNIMAS. A stock solution 
with a concentration of 1 mg/ml of each chalcone compound was initially prepared. This was 
subsequently diluted to 400 ).tg/ml, and two-fold serial dilution was then carried out to obtain 
the concentrations of 200 ).tg/ml, 100 Ilg/ml, 50 Ilg/ml, 25 ).tg/ml, 12.5 ).tg/ml, 6.125 ).tg/ml, 
3.125 Ilg/ml, and 1.563 ).tg/ml. 
The positive control used was TritonX-100. This was prepared by diluting 20 ).tl stock 
. n in 980 III complete culture medium. In addition, the complete culture medium served 
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